
    
      This study consisted of a Phase I non-randomized dose escalation phase to determine the
      maximum tolerated dose and a randomized Phase II component to assess preliminary efficacy.
      Nanoparticle paclitaxel was administered by intracoronary catheter following either
      successful and uncomplicated stenting of de novo lesions in native coronary arteries or
      following successful and uncomplicated balloon angioplasty of instent restenosis (ISR)
      lesions.
    
  